接受onabotulinumtoxinA与骶神经调节治疗难治性急迫性尿失禁女性的治疗反应与满意度相关特征
基于ROSETTA试验数据,分析接受onabotulinumtoxinA或骶神经调节治疗的难治性急迫性尿失禁女性,基线特征与治疗反应及满意度的关联。结果显示较高基线尿失禁发作次数与两种治疗反应均相关,而年龄较大、体重指数较高及功能合并症指数较高与onabotulinumtoxinA组反应降低相关。
要点
- 较高基线尿失禁发作次数与两种治疗中每日急迫性尿失禁发作减少更多相关(各p<0.001)。
- 年龄增加与两种治疗中尿失禁发作减少较少相关(p<0.001)。
- onabotulinumtoxinA组中较高年龄和功能合并症指数与达到50%以上发作减少的几率降低相关。
核心结论
- 年龄较大、多种合并症及功能与健康相关生活质量较低的女性,相比骶神经调节,接受onabotulinumtoxinA治疗难治性急迫性尿失禁的治疗反应和满意度较低。
研究设计与样本
- 分析ROSETTA(难治性膀胱过度活动症:骶神经调节与肉毒毒素评估)试验的数据。
主要发现
- onabotulinumtoxinA组中HUI-3评分较高与每日急迫性尿失禁发作减少更多相关,两组中基线尿失禁发作次数较高与发作减少更多相关(各p<0.001)。
- 两组中年龄增加与尿失禁发作减少较少相关(p<0.001)。
- 体重指数增加与每次治疗后达到50%以上尿失禁发作减少的几率降低相关(校正OR 0.82/5分,95%CI 0.70-0.96)。
- 仅在onabotulinumtoxinA组中,年龄较大(校正OR 0.44/10年,95%CI 0.30-0.65)和功能合并症指数较高(校正OR 0.84/1分,95%CI 0.71-0.99)与达到50%以上急迫性尿失禁发作减少的几率降低相关(分别为p<0.001和p=0.041)。
- onabotulinumtoxinA组中HUI-3评分较高与满意度增加相关(p=0.002),年龄较高与满意度较低相关(p=0.001)。
关键数值与推荐
- 治疗反应定义1:6个月内每日平均急迫性尿失禁发作减少。
- 治疗反应定义2:6个月内急迫性尿失禁发作减少50%或以上。
- 满意度评估使用OAB-S(膀胱过度活动症满意度)问卷。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to identify clinical and demographic characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation therapies. MATERIALS AND METHODS: We analyzed data from the ROSETTA (Refractory Overactive Bladder: Sacral NEuromodulation versus BoTulinum Toxin Assessment) trial. Baseline participant characteristics and clinical variables were associated with 2 definitions of treatment response, including 1) a reduction in mean daily urgency incontinence episodes during 6 months and 2) a 50% or greater decrease in urgency incontinence episodes across 6 months. The OAB-S (Overactive Bladder-Satisfaction) questionnaire was used to assess satisfaction. RESULTS: A greater reduction in mean daily urgency incontinence episodes was associated with higher HUI-3 (Health Utility Index-3) scores in the onabotulinumtoxinA group and higher baseline incontinence episodes (each p <0.001) in the 2 groups. Increased age was associated with a lesser decrease in incontinence episodes in the 2 groups (p <0.001). Increasing body mass index (adjusted OR 0.82/5 points, 95% CI 0.70-0.96) was associated with reduced achievement of a 50% or greater decrease in incontinence episodes after each treatment. Greater age (adjusted OR 0.44/10 years, 95% CI 0.30-0.65) and a higher functional comorbidity index (adjusted OR 0.84/1 point, 95% CI 0.71-0.99) were associated with reduced achievement of a 50% or greater decrease in urgency incontinence episodes in the onabotulinumtoxinA group only (p <0.001 and 0.041, respectively). In the onabotulinumtoxinA group increased satisfaction was noted with higher HUI-3 score (p = 0.002) but there was less satisfaction with higher age (p = 0.001). CONCLUSIONS: Older women with multiple comorbidities, and decreased functional and health related quality of life had decreased treatment response and satisfaction with onabotulinumtoxinA compared to sacral neuromodulation for refractory urgency incontinence.
引用
- Richter HE, Amundsen CL, Erickson SW, et al. Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence. J Urol. 2017. PMID: 28501541. doi:10.1016/j.juro.2017.04.103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。